Zurzuvae | search
Click here to view Zurzuvae news from 60+ newspapers.
Bookmark or Share- FDA Approves First Oral Treatment for Postpartum DepressionToday, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode...
- Zuranolone - WikipediaZuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. [5] [6] It is taken by mouth. [5] The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.
- What to Know About Zurzuvae, the New Pill to Treat Postpartum ...The medication, zuranolone (brand name: Zurzuvae™), has been shown to ease postpartum depression in just three days, and is expected to be available in late fall. Price and insurance coverage details have not yet been announced. The drug was developed by Sage Therapeutics in partnership with Biogen.
- ZURZUVAE® (zuranolone) C-IV | Official Patient WebsiteZURZUVAE is a prescription medicine used to treat adults with postpartum depression (PPD). It is not known if ZURZUVAE is safe and effective in children. IMPORTANT SAFETY INFORMATION. What is the most important information I should know about ZURZUVAE?
- Zurzuvae: Uses, Dosage, Side Effects, Warnings - Drugs.comZurzuvae is a neuroactive steroid that acts on the GABA-A receptors as a positive allosteric modulator. Zurzuvae was developed as an improvement to brexanolone (Zulresso), which is only available as an intravenous injection, whereas Zurzuvae can be taken as a once-daily capsule.
More
